Livagen

What it is

Livagen belongs to the cytogens, the synthetic short peptides of the Khavinson school. According to the developers, the sequence lysine, glutamic acid, aspartic acid, alanine was specifically synthesized on the basis of the amino acid analysis of liver polypeptide preparations. Its natural counterpart is Ventvil, a polypeptide complex from the liver that a 2020 review by the group discusses together with Livagen.

The sequence is closely related to other peptides in the series. The first three building blocks correspond to Vesugen, the vascular peptide. This shows how close together the molecules of the school are, and explains why the claimed organ specificity is not always sharp on closer inspection.

How it is supposed to work

The basic idea of bioregulation: with age, the genetic material in cells becomes condensed, genes are silenced and organs lose function. Short peptides are supposed to reach the cell nucleus and specifically undo this condensation. For Livagen there is a separate line of research on this, carried by a group in Tbilisi that has partly published with Khavinson.

In blood cells from people between 75 and 88 years of age, Livagen activated ribosomal genes in the test tube, that is, the machinery of protein synthesis, and loosened condensed chromatin. Unlike some related peptides, it also reached particularly tightly packed regions on chromosomes 1 and 9. In lymphocytes from 80- to 91-year-olds, it also reduced chromosome damage caused by cobalt.

In parallel, Livagen acts directly on liver cells. In cultures of rat hepatocytes from animals between 1 and 24 months of age, it increased protein synthesis, most strongly in the cells of old animals. Epitalon, the pineal gland peptide, did not do this in the same cells. This points to a certain tissue specificity.

A side finding from the laboratory: in human serum, Livagen inhibited enzymes that break down the body’s own enkephalins, that is, pain-dampening messengers, and did so more strongly than known inhibitors such as puromycin and leupeptin. It did not bind to opioid receptors. Whether this plays a role in the body has not been studied by anyone.

Does it survive digestion?

A practical question for any peptide in capsule form is whether it survives the gut. Here Livagen has an interesting finding: the protein-splitting enzymes of the small intestine do not cleave it, not even to a small extent. After two weeks of oral administration in rats, it changed the activity of digestive enzymes, in old animals towards the values of young animals. In the test tube, Livagen inhibited a dipeptidase of the small intestine by 50 percent.

This is not proof that the peptide reaches the liver in humans. But it is one of the few indications in the bioregulator literature that oral administration can have any measurable effect at all.

What the studies show

Case series in chronic hepatitis (patent)

European patent EP1325026 describes 23 patients between 32 and 53 years of age with chronic persistent hepatitis that had existed for 10 to 20 years. They received Livagen as an intramuscular injection. After treatment, ALT fell from 53.1 to 40.8, bilirubin from 26.3 to 21.7 and the inflammatory immunoglobulin IgM from 3.80 to 1.50 g/l; 51 percent had less pain. A control group of 12 patients is mentioned, but its values are not reported.

Poisoned liver and liver tumor in rats (patent)

In the carbon tetrachloride model, Livagen clearly reduced the proportion of fatty liver cells and normalized protein, bilirubin, cholesterol and liver enzymes by day 20. In 37 rats with a transplanted liver tumor, the tumor was 2.5 times smaller on day 30, and the mean survival time was 68 instead of 55 days.

Chromatin in blood cells of very old people (2004)

Khavinson, Lezhava and Malinin treated leukocytes from people between 75 and 88 years of age with several short peptides. All of them activated ribosomal genes and loosened condensed chromatin; Livagen additionally reached highly condensed regions on chromosomes 1 and 9. A laboratory finding in isolated cells, not a clinical endpoint.

Stability in the gut (2005)

Timofeeva and colleagues showed that small-intestinal peptidases do not cleave Livagen. After two weeks of oral administration in rats, the enzyme activity of old animals approached that of young control animals.

Where the data stop

The only treatment in humans is described in a patent, not in a peer-reviewed journal. The control group is mentioned but not analyzed, randomization and blinding are missing, and the injections were intramuscular. Whether the capsule form achieves the same is open. The impressive animal figures also come from the developers’ patent and have not been independently replicated. ClinicalTrials.gov lists no study.

Several widespread claims go beyond the data. The chromatin findings concern blood cells in the test tube, not liver cells and not treated people. Fatty liver and alcohol-related liver damage, for which Livagen is often advertised, have never been specifically studied; the animal models concern poisoning, fibrosis and hepatitis. And an upregulation of phase II detoxification pathways, as is sometimes claimed, could not be found in any paper.

Status, approval and legal

Livagen is not an approved medicine in Germany or the EU. As a food supplement it would require authorization under the Novel Food Regulation (EU) 2015/2283, which does not exist. It is sold as a capsule product or research peptide by online retailers. It is not listed by name on the World Anti-Doping Agency’s prohibited list, but as a non-approved substance it falls under group S0 and is prohibited in sport at all times.

Safety

There are no systematic safety data in humans. The animal toxicology in the patent, with 72 mice after a single dose, 64 rats over 90 days and a test over 6 months, proceeded without reported harm, but these are the developers’ own data. In the test tube, Livagen inhibited enzymes that break down the body’s own enkephalins, as well as a dipeptidase of the gut; what this means in the body is unknown. Interactions with medicines that are broken down by the liver, or with hepatitis therapies, have never been studied. Anyone with active liver disease belongs in hepatological care, and this does not replace treatment. There are no data for pregnancy and breastfeeding, and with research-grade products, content and purity are unverified.

Sources

• Khavinson, EP1325026 – tetrapeptide Lys-Glu-Asp-Ala for stimulating liver cell function (animal data, toxicology, case series)
• Kuznik et al., Adv Gerontol 2020 – Ventvil and KEDA in liver animal models (review)
• Brodskii et al., Izv Akad Nauk Ser Biol 2001 – Livagen and protein synthesis in hepatocytes of young and old rats
• Khavinson, Lezhava, Malinin, Bull Exp Biol Med 2004 – short peptides and chromatin in leukocytes of very old people
• Khavinson et al., Bull Exp Biol Med 2002 – Livagen activates chromatin in lymphocytes of old people
• Lezhava and Jokhadze, Ann N Y Acad Sci 2007 – Livagen and cobalt in lymphocytes of 80- to 91-year-olds
• Timofeeva et al., Adv Gerontol 2005 – Livagen and digestive enzymes in rats of different ages
• Kost et al., Izv Akad Nauk Ser Biol 2003 – Livagen inhibits enkephalin-degrading enzymes in serum
• ClinicalTrials.gov – search for Livagen with no registered study
• NADA – Prohibited List 2026, informational German translation (group S0)